JP6798998B2 - コノトキシンペプチドの修飾および使用 - Google Patents

コノトキシンペプチドの修飾および使用 Download PDF

Info

Publication number
JP6798998B2
JP6798998B2 JP2017544555A JP2017544555A JP6798998B2 JP 6798998 B2 JP6798998 B2 JP 6798998B2 JP 2017544555 A JP2017544555 A JP 2017544555A JP 2017544555 A JP2017544555 A JP 2017544555A JP 6798998 B2 JP6798998 B2 JP 6798998B2
Authority
JP
Japan
Prior art keywords
pain
conotoxin peptide
peptide
pharmaceutically acceptable
conotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017544555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500385A (ja
JP2018500385A5 (enExample
Inventor
ショーン・ピー・アイアドナト
エルネスト・ジェイ・ムニョス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kineta Chronic Pain LLC
Original Assignee
Kineta Chronic Pain LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Chronic Pain LLC filed Critical Kineta Chronic Pain LLC
Publication of JP2018500385A publication Critical patent/JP2018500385A/ja
Publication of JP2018500385A5 publication Critical patent/JP2018500385A5/ja
Application granted granted Critical
Publication of JP6798998B2 publication Critical patent/JP6798998B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2017544555A 2014-11-07 2015-11-06 コノトキシンペプチドの修飾および使用 Active JP6798998B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462123123P 2014-11-07 2014-11-07
US62/123,123 2014-11-07
PCT/US2015/059613 WO2016073949A1 (en) 2014-11-07 2015-11-06 Modifications and uses of conotoxin peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020040876A Division JP2020090550A (ja) 2014-11-07 2020-03-10 コノトキシンペプチドの修飾および使用

Publications (3)

Publication Number Publication Date
JP2018500385A JP2018500385A (ja) 2018-01-11
JP2018500385A5 JP2018500385A5 (enExample) 2018-12-13
JP6798998B2 true JP6798998B2 (ja) 2020-12-09

Family

ID=55909927

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017544555A Active JP6798998B2 (ja) 2014-11-07 2015-11-06 コノトキシンペプチドの修飾および使用
JP2020040876A Withdrawn JP2020090550A (ja) 2014-11-07 2020-03-10 コノトキシンペプチドの修飾および使用
JP2022010036A Pending JP2022063872A (ja) 2014-11-07 2022-01-26 コノトキシンペプチドの修飾および使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020040876A Withdrawn JP2020090550A (ja) 2014-11-07 2020-03-10 コノトキシンペプチドの修飾および使用
JP2022010036A Pending JP2022063872A (ja) 2014-11-07 2022-01-26 コノトキシンペプチドの修飾および使用

Country Status (12)

Country Link
US (2) US11014970B2 (enExample)
EP (1) EP3215172B1 (enExample)
JP (3) JP6798998B2 (enExample)
KR (1) KR102623475B1 (enExample)
CN (1) CN107249616A (enExample)
AU (2) AU2015342767B2 (enExample)
CA (1) CA2966865C (enExample)
ES (1) ES2950901T3 (enExample)
HK (1) HK1244201A1 (enExample)
IL (2) IL284236B2 (enExample)
TW (2) TWI708790B (enExample)
WO (1) WO2016073949A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI708790B (zh) 2014-11-07 2020-11-01 美商奇尼塔慢性疼痛有限責任公司 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途
RU2731217C2 (ru) * 2016-11-28 2020-08-31 Общество с ограниченной ответственностью "Синейро" Аналог альфа-конотоксина RgIA для лечения боли
US10947274B1 (en) * 2018-05-01 2021-03-16 University Of Utah Research Foundation Synthetic analgesic peptides of RgIA analogs
KR102117106B1 (ko) 2018-09-14 2020-06-01 대한민국(환경부 국립생물자원관장) N형 칼슘채널 차단 활성을 갖는 긴호랑거미 유래 알지신-ⅰ 펩타이드 및 이의 용도
US11612661B2 (en) 2019-01-04 2023-03-28 Kineta Chronic Pain, Llc Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
AU2019418319B2 (en) * 2019-01-04 2025-08-21 Pacira Pharmaceuticals, Inc. Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
JP2023523899A (ja) * 2020-04-09 2023-06-08 ジーエルオー ファーマ，インク． ニコチン性アセチルコリン受容体活性を阻害するためのペプチド組成物および方法
KR20230031884A (ko) * 2020-06-03 2023-03-07 유타대학연구재단 형태적으로 제약된 α-RGIA 유사체
CN114805492B (zh) * 2022-03-15 2025-07-22 上海元炘执药科技有限公司 一种用于抑制电压门控钠离子通道1.4的芋螺毒素kiiia突变体及其制备方法和应用
CN115286700B (zh) * 2022-08-22 2024-11-19 中国海洋大学 一种具有血浆稳定性的镇痛多肽
CN118184744A (zh) * 2024-03-29 2024-06-14 广西大学 一种靶向神经型乙酰胆碱受体的多肽分子及其制备方法和应用
CN119912549A (zh) * 2024-12-29 2025-05-02 中国人民解放军军事科学院防化研究院 一类脂肪醛修饰的芋螺肽及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595972A (en) 1993-06-29 1997-01-21 University Of Utah Research Foundation Conotoxin peptides
US6797808B1 (en) 1999-01-29 2004-09-28 University Of Utah Research Foundation α-conotoxin peptides
HUP0203504A3 (en) 1999-10-18 2005-03-29 Akzo Nobel Nv Modified peptides and peptidomimetics for use in immunotherapy
EP1578787B1 (en) 2002-12-02 2012-11-14 Xenome Ltd Novel chi-conotoxin peptides (-ii)
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
EP1770099A1 (en) * 2005-09-28 2007-04-04 University of Geneva Method of producing a modified (poly)peptide
US7745573B2 (en) 2006-02-17 2010-06-29 Polychip Pharmaceuticals Pty Ltd. Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
CA2566832A1 (en) * 2006-04-13 2007-10-13 The University Of Queensland Cyclised alpha-conotoxin peptides
US9284358B2 (en) * 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
EP2310407A4 (en) 2008-04-08 2011-09-14 Aileron Therapeutics Inc BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES
DE102009050885A1 (de) * 2009-10-27 2011-04-28 Behr Gmbh & Co. Kg Luftausströmer
WO2014194284A1 (en) 2013-05-31 2014-12-04 Mcintosh J Michael Conotoxin peptides, pharmaceutical compositions and uses thereof
TWI708790B (zh) 2014-11-07 2020-11-01 美商奇尼塔慢性疼痛有限責任公司 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途
US11612661B2 (en) 2019-01-04 2023-03-28 Kineta Chronic Pain, Llc Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions

Also Published As

Publication number Publication date
KR102623475B1 (ko) 2024-01-09
CN107249616A (zh) 2017-10-13
IL284236B2 (en) 2023-04-01
HK1244201A1 (zh) 2018-08-03
ES2950901T3 (es) 2023-10-16
JP2018500385A (ja) 2018-01-11
IL252152B (en) 2021-07-29
TWI777260B (zh) 2022-09-11
JP2020090550A (ja) 2020-06-11
WO2016073949A1 (en) 2016-05-12
IL284236B (en) 2022-12-01
AU2015342767A1 (en) 2017-06-15
EP3215172A1 (en) 2017-09-13
US11618772B2 (en) 2023-04-04
US20180362599A1 (en) 2018-12-20
US11014970B2 (en) 2021-05-25
TW201629085A (zh) 2016-08-16
IL252152A0 (en) 2017-07-31
EP3215172A4 (en) 2018-07-25
EP3215172B1 (en) 2023-04-26
IL284236A (en) 2021-08-31
TWI708790B (zh) 2020-11-01
CA2966865A1 (en) 2016-05-12
KR20170083574A (ko) 2017-07-18
AU2021212006B2 (en) 2023-08-31
US20210122792A1 (en) 2021-04-29
JP2022063872A (ja) 2022-04-22
CA2966865C (en) 2023-03-21
AU2021212006A1 (en) 2021-08-26
TW202120525A (zh) 2021-06-01
AU2015342767B2 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
JP6798998B2 (ja) コノトキシンペプチドの修飾および使用
TWI686205B (zh) 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽，其醫藥組合物及用途
CN104693302A (zh) 包含额外的二硫键的胰岛素衍生物
JP2021515759A (ja) コンプスタチン類似体及びその医療用途
JP2022545916A (ja) コンプスタチン類似体及びその医学的使用
US10947274B1 (en) Synthetic analgesic peptides of RgIA analogs
CN118159550B (zh) 经修饰的多肽及其在镇痛领域的应用
TW202438508A (zh) TNF-α結合劑及其使用方法

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20180615

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200310

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200814

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200825

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200827

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201027

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201119

R150 Certificate of patent or registration of utility model

Ref document number: 6798998

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250